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ABSTRACT
Introduction An estimated 69 million traumatic brain 
injuries (TBI) occur each year worldwide, with most in 
low- income and middle- income countries. The CRASH-3 
randomised trial found that intravenous administration 
of tranexamic acid within 3 hours of injury reduces head 
injury deaths in patients sustaining a mild or moderate TBI. 
We examined the cost- effectiveness of tranexamic acid 
treatment for TBI.
Methods A Markov decision model was developed to 
assess the cost- effectiveness of treatment with and 
without tranexamic acid, in addition to current practice. 
We modelled the decision in the UK and Pakistan from a 
health service perspective, over a lifetime time horizon. 
We used data from the CRASH-3 trial for the risk of death 
during the trial period (28 days) and patient quality of 
life, and data from the literature to estimate costs and 
long- term outcomes post- TBI. We present outcomes as 
quality- adjusted life years (QALYs) and 2018 costs in 
pounds for the UK, and US dollars for Pakistan. Incremental 
cost- effectiveness ratios (ICER) per QALY gained were 
estimated, and compared with country speciic cost- 
effective thresholds. Deterministic and probabilistic 
sensitivity analyses were also performed.
Results Tranexamic acid was highly cost- effective 
for patients with mild TBI and intracranial bleeding or 
patients with moderate TBI, at £4288 per QALY in the UK, 
and US$24 per QALY in Pakistan. Tranexamic acid was 
99% and 98% cost- effective at the cost- effectiveness 
thresholds for the UK and Pakistan, respectively, 
and remained cost- effective across all deterministic 
sensitivity analyses. Tranexamic acid was even more 
cost- effective with earlier treatment administration. 
The cost- effectiveness for those with severe TBI was 
uncertain.
Conclusion Early administration of tranexamic acid is 
highly cost- effective for patients with mild or moderate TBI 
in the UK and Pakistan, relative to the cost- effectiveness 
thresholds used. The estimated ICERs suggest treatment 
is likely to be cost- effective across all income settings 
globally.
INTRODUCTION
It is estimated that 69 million traumatic brain 
injuries (TBIs) occur each year worldwide, 
resulting mainly from road traffic crashes 
and falls.1 The incidence of TBI is increasing, 
and this trend is expected to continue as the 
global population ages, and as motor vehicle 
use increases.2 While the incidence of TBI is 
highest among high- income countries, the 
burden is greatest in low- income and middle- 
income countries (LMICs), which accounts 
Key question
What is already known?
 Ź Tranexamic acid is cost- effective in reducing bleed-
ing deaths in trauma and postpartum haemorrhage, 
but there is no evidence of its cost- effectiveness for 
those suffering traumatic brain injury (TBI).
 Ź Evidence from the CRASH-3 randomised trial 
showed that the early administration of tranexamic 
acid reduces head injury- related deaths in patients 
sustaining a mild TBI with intracranial bleeding or a 
moderate TBI.
What are the new indings?
 Ź Compared with the assumed country- speciic cost- 
effectiveness thresholds, tranexamic acid is highly 
cost- effective in treating patients with moderate TBI 
or mild TBI with intracranial bleeding, in both the UK 
and Pakistan.
 Ź Treatment was highly likely to cost- effective in 
probabilistic sensitivity analyses in both settings, 
and remained cost- effective across all deterministic 
sensitivity analyses.
What do the new indings imply?
 Ź Providing tranexamic acid for mild and moderate TBI 
is likely to be cost- effective across all income set-
tings, with the potential to prevent many thousands 
of premature deaths globally each year.
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for almost three- quarters of all TBIs.1 TBI can result in 
long- term disability or death, and can have a substantial 
impact on the individual’s family due to loss of income 
and informal caregiving. It also impacts on the economy 
due to healthcare expenditure and productivity loss.2 
Around 8% of all TBIs are classified as severe (Glasgow 
Coma Scale (GCS) score of 3–8), which are more likely 
to result in death or long- lasting disability, compared 
with mild (GCS of 13–15) or moderate (GCS 9–12) head 
injury, for which the risk of death is lower, but still consid-
erable.1 3
Tranexamic acid reduces bleeding by inhibiting the 
breakdown of blood clots. Large randomised controlled 
trials (RCTs) have shown its effectiveness and cost- 
effectiveness in reducing deaths from traumatic and 
postpartum haemorrhage.4–7 More recently, the multina-
tional CRASH-3 trial assessed the impact of tranexamic 
acid on head injury deaths when administered within 
3 hours of TBI, and showed a reduction in head injury 
deaths for those sustaining a mild or moderate head 
injury.8 However, its cost- effectiveness for this indication 
is yet to be assessed.
Since healthcare resources are constrained, it is 
important to ensure that any policy decision to fund 
tranexamic acid treatment in this indication results in 
overall net health gains. This will only occur if tranexamic 
acid provision replaces a less cost- effective alternative 
that is currently provided. For this reason, as prespecified 
in the trial protocol, we present an economic evaluation 
of tranexamic acid following TBI using the results from 
the CRASH-3 trial, combined with a decision modelling 
approach to estimate the long- term costs and benefits of 
treatment.9
METHODS
Analysis
The economic analysis assessed the cost- effectiveness of 
treating patients sustaining a TBI with tranexamic acid, 
versus no tranexamic acid treatment, in addition to the 
current standard of care. The CRASH-3 trial included 
head injury patients (without significant extracranial 
bleeding) treated within 3 hours of their injury, with 
either a GCS score of 12 or lower, or with GCS 13–15 and 
any intracranial bleeding on their CT scan.8 Patients in 
the trial received a loading dose of 1 g of tranexamic acid 
infused over a 10 min period immediately after rando-
misation, followed by an intravenous infusion of 1 g over 
8 hours.8
The trial found that tranexamic acid reduced head 
injury deaths among those with TBI, with a risk ratio of 
0.94 (95% CI 0.86 to 1.02).8 However, there was evidence 
that people with mild TBI and intracranial bleeding 
(GCS score 13–15), or moderate TBI (GCS score of 9–12) 
had a greater benefit from tranexamic acid treatment, in 
terms of a reduction in head injury death (risk ratio (RR) 
0.78, 95% CI 0.64 to 0.95) compared with those with a 
severe head injury (GCS score of 3–8, RR 0.99, 95% CI 
0.91 to 1.07). For this reason, the mild and moderate 
CRASH-3 population was used as the base case popula-
tion, excluding those with severe head injury.
We also evaluated the cost- effectiveness of tranexamic 
acid for alternative populations of patients, as sensi-
tivity analyses. First, we considered people sustaining a 
TBI of any severity with both pupils reactive (RR 0.87 
95% CI 0.77 to 0.98), while excluding those with either 
pupil unreactive (RR 1.03 95% CI 0.94 to 1.13). We 
also considered the cost- effectiveness of tranexamic 
acid in those sustaining a severe TBI, as there is some 
evidence to suggest that those in high- income coun-
tries benefit from treatment with tranexamic acid (RR 
0.9, 95% CI 0.74 to 1.08), particularly when excluding 
severe patients with a GCS score of 3 or bilateral unre-
active pupils (RR 0.62, 95% CI 0.41 to 0.96). There is 
no evidence of a benefit to patients sustaining a severe 
TBI in LMICs in either of these subgroups (see online 
supplementary materials).
The model evaluates the cost- effectiveness of 
tranexamic acid from a health service perspective in the 
UK and Pakistan, the two largest recruiting countries in 
the CRASH-3 trial (23% and 41%, respectively). This also 
allowed for cost- effectiveness to be assessed in a high- 
income and a lower- middle- income country.
The model was analysed over a lifetime time horizon 
with costs presented in 2018 pounds for the UK, and US 
dollars for Pakistan. Outcomes are presented as life- years, 
and quality- adjusted life years (QALYs). The model esti-
mates the incremental cost- effectiveness ratio (ICER) 
by dividing the incremental costs by the incremental 
health outcomes, for patients receiving tranexamic acid 
compared with those not receiving tranexamic acid, 
to give a cost per life year or QALY gained. The mean 
age of individuals entering the model was 42 years 
old, as derived from the CRASH-3 trial. Both costs and 
outcomes were discounted equally, at a rate of 3.5% for 
the UK, according to National Institute for Health and 
Care Excellence (NICE) guidance, and a rate of 3% for 
Pakistan according to the International Decision Support 
Initiative Economic Evaluation Reference Case.10 11 Alter-
native discount rates (0% and 6%) were used in sensitivity 
analyses. The cost- effectiveness model was developed in 
Microsoft Excel, with the analysis of trial data performed 
in STATA V.16.
Model structure
A Markov model with time- variant transition probabilities 
captured the long- term outcomes associated with head 
injury, and is shown in figure 1. It consists of two health 
states, alive and dead, and includes the risk of death 
during the first 28 days of the trial from both head inju-
ries and non- head injuries along with estimates of longer- 
term mortality. The model uses a daily cycle length for 
the first year, to allow the events during the trial period 
to be accurately modelled, followed by an annual cycle 
length thereafter.
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Model parameters
Clinical outcomes
The 28- day risk of head injury and non- head injury death 
for the placebo group were derived from the CRASH-3 
trial, with the risk in high- income countries used to esti-
mate the risk in the UK, and LMICs used to estimate the 
risk in Pakistan (table 1).8 A risk ratio of head injury death 
was applied for patients receiving tranexamic acid, as 
derived directly from the CRASH-3 trial. The risk of non- 
head injury death was equal for placebo and tranexamic 
acid groups.
Following the 28- day trial follow- up period, the risk 
of death was assumed equal for people treated with and 
without tranexamic acid. Standardised mortality ratios 
(SMRs) were used to account for the higher risk of 
death post- TBI compared with the general population. 
SMRs were derived from a study which included a variety 
of head injury severities, which estimated an SMR of 4 
for the first year following injury, and 2.26 thereafter, 
compared with a group of matched community controls.12 
These SMRs were applied relative to age based, general 
population mortality estimates specific to both the UK 
and Pakistan.13 14 It was assumed that this excess risk of 
death continued throughout the duration of the model. 
A sensitivity analysis that excluded this long- term risk of 
death was performed to assess the impact of this param-
eter. The long- term survival estimates produced by the 
model are shown in the online supplementary materials.
There was no evidence of an increase in the risk of 
adverse events following tranexamic acid use in the 
CRASH-3 trial, therefore, they were not included in the 
model.
Utility
In the CRASH-3 trial, there was little difference between 
the Disability Rating Scale (DRS) scores reported for 
those with mild and moderate TBI (tranexamic acid 3.12 
(SD: 5.6) vs placebo 2.91 (5.1), with lower scores indi-
cating less disability).
Utility values were not collected as part of the CRASH-3 
trial. A systematic review and EQ- 5D utility mapping study 
was identified, which reported utility values for patients 
with TBI, based on their level of disability, as defined by 
the Glasgow Outcome Scale (GOS).15 In the absence of 
GOS outcomes in the CRASH-3 trial, we used the DRS 
scores of CRASH-3 trial patients to estimate the propor-
tion of patients in each GOS category, using a qualitative 
estimation involving a clinical expert. This resulted in an 
estimated 3094 patients with a good recovery, 1288 with 
moderate disability, 677 with severe disability and 124 in a 
vegetative state. The utility values for each GOS category 
were then used to estimate the mean utility of CRASH-3 
patients, using a weighted average. This mapping process 
resulted in an estimated utility of 0.75 for the mild and 
moderate TBI population, using a UK value set. This 
utility value was also used for Pakistan, in the absence of 
a value set for the Pakistan population (table 1). The esti-
mated mapping of DRS scores to GOS outcomes is shown 
in the supplementary materials, with clinical input used 
in the mapping estimation.
Due to the uncertainty around the utility estimates, a 
sensitivity analysis considered an alternative method to 
estimate GOS outcomes among CRASH-3 patients, using 
a study reporting both GCS scores at injury and GOS 
outcomes (see online supplementary materials).3 15 This 
produced a higher utility of 0.79. An alternative sensi-
tivity analysis considered a lower utility value of 0.63 (in 
both treatment groups), based on the midpoint of mild 
and moderate TBI utility values, as reported in a Swiss 
quality of life study.16 This was used to assess the impact of 
a lower utility estimate on the cost- effectiveness.
It was assumed that individuals who died within the 
28- day study period had a utility of 0 between their injury 
and death. Mean utility values were adjusted by age, based 
on UK general population utility estimates, to account 
for declining utility with age.17
Costs
The model captured the costs associated with providing 
treatment, including the cost of tranexamic acid, needle 
and syringe, and nurse administration time, which were 
applied to the tranexamic acid arm only (table 1). The 
total cost of tranexamic acid (2 g total dose) was derived 
from the British National Formulary (£6 per person) for 
the UK, and from local online drug systems for Pakistan 
(US$1.92 per person).18 19 The cost of a 100 mL and a 
Figure 1 Economic model structure. TBI, traumatic brain injury.
 o
n
 Septem
ber 15, 2020 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2020-002716 on 2 September 2020. Downloaded from 
4 Williams J, et al. BMJ Global Health 2020;5:e002716. doi:10.1136/bmjgh-2020-002716
BMJ Global Health
500 mL sodium chloride infusion bag was derived from 
the same sources for both settings (£3.25 and US$0.46, in 
total).18 19 The costs of needles and syringes were derived 
from an NICE costing template for the UK, and from a 
global study for Pakistan.20 21
In the CRASH-3 trial, tranexamic acid was given in an 
emergency department setting. The nurse time to admin-
ister tranexamic acid was assumed to be 21 min (as per 
the CRASH-2 trial, involving the same treatment admin-
istration), with hourly nurse costs derived from UK social 
Table 1 Base- case model parameters
Parameter Value Distribution Source
Tranexamic acid risk ratio treatment effect     
  Head injury 0.78 Log normal (μ=−0.248, σ=0.1) CRASH-3 trial8
  Non- head injury 1 N/A CRASH-3 trial8
28 risk of death     
  Head injury death (UK) 0.061 Beta (α=42, β=643) CRASH-3 trial8
  Head injury death (Pakistan) 0.079 Beta (α=165, β=1919) CRASH-3 trial8
  Non- head injury death (UK) 0.018 Beta (α=12, β=673) CRASH-3 trial8
  Non- head injury death (Pakistan) 0.005 Beta (α=11, β=2073) CRASH-3 trial8
Long- term standardised mortality ratios     
  First year, postinjury 4.00 Normal (95% CI 3.27 to 4.90) McMillan12
  Beyond irst year, postinjury 2.26 Normal (95% CI 1.84 to 2.77) McMillan12
Utility     
  Good recovery 0.894 Beta (α=50, β=5.9) Ward Fuller15
  Moderate disability 0.675 Beta (α=30.5, β=14.7) Ward Fuller15
  Severe disability 0.382 Beta (α=10.9, β=17.7) Ward Fuller15
  Vegetative state −0.178 Beta (α=16.1, β=−106.3) Ward Fuller15
  Average utility (weighted average of above 
disabilities)*
0.75 By component (based on above 
distributions for disabilities)ˆ
Calculated
Costs (UK)     
  Tranexamic acid (full dose) £6.00 N/A BNF18
  Sodium chloride £3.25 N/A BNF18
  Needle and syringe £0.05 N/A NICE20
  Hospital cost £4741 Gamma (k=31.4, θ=0.43)† NHS Reference 
costs23/CRASH-3 
trial8
  Monitoring costs (irst year post, injury) £11 662 By component (see online 
supplementary materials)
Beecham et al25 /
Lecky et al26
  Monitoring costs (after irst year, postinjury) £2505 By component (see online 
supplementary materials)
Lecky et al26/expert 
opinion
Costs (Pakistan)     
  Tranexamic acid (full dose) US$1.92 N/A Drug information 
system19
  Sodium chloride US$0.46 N/A Drug information 
system19
  Needle and syringe US$0.20 N/A Dziekan et al21
  Hospital cost US$92 Gamma (k=21.8, θ=0.34)† WHO CHOICE24/
CRASH-3 trial8
  Monitoring costs US$0 N/A Expert opinion
*Deterministic and probabilistic average utility values are estimated from a weighted average of CRASH-3 patients with good recovery 
(3094), moderate disability (1288), severe disability (677) and vegetative state (124).
†Gamma distribution for hospital length of stay (UK: 13.7 days, Pakistan: 7.4 days).
BNF, British National Formulary; N/A, not available; NHS, National Health Service; NICE, National Institute for Health and Care Excellence.
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service costs.7 22 Administration of tranexamic acid in 
Pakistan was assumed to be performed by a postgraduate 
doctor, earning an estimated US$5.20/hour, with costs 
derived from a trial hospital in Pakistan.
Inpatient hospital costs were derived from UK National 
Health Service reference costs, and WHO- CHOICE 
costs for Pakistan.23 24 There was little difference in 
hospital length of stay for those treated with and without 
tranexamic acid, but it differed between high- income 
countries (13.7 days) and low- income countries (7.4 
days). While the majority of patients were discharged 
home in the trial (85% in both arms), some patients 
were discharged to another hospital during their stay 
(tranexamic acid: 7.7%, placebo: 8.2%) or remained in 
hospital beyond 28 days (tranexamic acid: 7.3%, placebo: 
6.4%), which was not captured in our calculation of 
length of stay. However, since these were balanced across 
arms, and since the length of stay was assumed the same, 
hospital costs did not impact on the incremental costs, 
and therefore, did not impact the cost- effectiveness in 
the base- case analysis. A sensitivity analysis was performed 
to assess the impact of this assumption, by modelling the 
differences in mean length of stay between treatment 
arms for the UK (tranexamic acid: 14 days, placebo: 13.3 
days) and Pakistan (tranexamic acid: 7.3 days, placebo: 
7.4 days).
Patients were assumed to incur monitoring costs post- 
discharge, which included primary care visits and outpa-
tient clinic visits, as well as community care such as formal 
carers and rehabilitation. For the UK, first year moni-
toring costs were derived from a UK costing study, for 
those with good recovery, moderate disability and severe 
disability, with an estimated cost of £11,662.25 Long- term 
monitoring costs (after the first year) were derived from 
a previous UK health technology assessment, with costs 
estimated by expert opinion.26 The average cost was esti-
mated to be £2505 per year and was assumed to occur 
until the patient died. Due to the uncertainty in these 
costs, we explored the impact of excluding monitoring 
costs beyond the first- year postinjury, and applying moni-
toring costs until 5 years postinjury only, in sensitivity 
analyses. For Pakistan, the model assumes no routine 
monitoring is provided postdischarge, based on input 
from local trial collaborators.
Costs were inflated to 2018 prices using the UK hospi-
tals and community service index, and gross domestic 
product (GDP) per capita indices derived from the World 
Bank for Pakistan.22 27
Cost-effectiveness threshold
We used the lower bound of the £20 000 to £30 000 per 
QALY cost- effectiveness threshold stated by NICE for the 
UK.10 The cost- effectiveness threshold in Pakistan was 
derived from a study of thresholds for LMICs and inflated 
to 2018 values.28 This gave an estimated threshold of 
US$158 per QALY threshold (estimated as 10.75% of 
GDP per capita). Our results assume that tranexamic 
acid was cost- effective when the estimated ICERs fell 
below these cost- effectiveness thresholds.
Sensitivity analyses
The main analysis was performed using probabilistic 
sensitivity analyses to simultaneously capture the uncer-
tainty in model parameters. Distributions were assigned 
to each probabilistic parameter, with each sampled simul-
taneously across 1000 Monte Carlo simulations. We also 
ensured that the probability of cost- effectiveness did not 
increase with higher numbers of simulations. One- way 
deterministic sensitivity analyses were also performed to 
assess the sensitivity of specific parameters on the cost- 
effectiveness estimates, and are presented relative to the 
base case as a tornado diagram. The input parameters for 
alternative model populations, including patients with 
both pupils reactive and those sustaining a severe TBI, 
are presented in the supplementary materials.
Patient and public involvement
Patient and public involvement (PPI) groups were 
involved in various stages of the CRASH-3 trial, including 
the trial design, consent procedure, outcome data collec-
tion, interpretation of results and the results dissemina-
tion strategy. Although the cost- effectiveness analysis did 
not involve explicit PPI input, the model does capture 
the key outcomes of the CRASH-3 trial. The PPI groups 
included people at risk of, or suffering, TBI and chari-
table organisations involved with supporting people who 
have suffered trauma or TBI.29
RESULTS
The costs, life years and QALYs associated with and 
without tranexamic acid treatment are presented in 
table 2. In the base- case analysis, tranexamic acid is 
highly cost- effective in both the UK and Pakistan for 
those sustaining a moderate TBI or mild TBI with intrac-
ranial bleeding, with both ICERs below their respective 
willingness to pay thresholds.
Compared with the UK cost- effectiveness threshold 
of £20 000/QALY, the ICER for those with mild and 
moderate head injury is considerably lower at £4288/
QALY, with a 99% probability of being cost- effective at 
this threshold (figure 2). For Pakistan, the ICER was 
US$24/QALY, and is again lower than the corresponding 
cost- effectiveness threshold of US$158/QALY, with a 
98% probability to be cost- effective. When considering 
life years only, the ICER was £3078 per life year gained in 
the UK, and US$17 per life year gained in Pakistan.
There was little difference between the deterministic 
base- case ICERs, and the average ICER estimated across 
all probabilistic sensitivity analysis simulations (£4288 vs 
£4286 for the UK and US$24.01 vs US$24.38 for Pakistan, 
respectively).
For the UK, the cost of purchasing and administering 
tranexamic acid represented a very small proportion of 
the incremental costs (3%), with long- term monitoring 
costs contributing to most of the incremental costs for 
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the tranexamic acid group (97%). These higher costs are 
due to a higher proportion of patients surviving when 
receiving tranexamic acid, since monitoring costs per 
person were equal for both treatment groups. In contrast, 
for Pakistan, the costs associated with tranexamic acid 
treatment, and treatment administration, represented all 
of the incremental costs between the two groups, since 
there were no monitoring costs. The total life years and 
QALYs predicted by the model were higher for the UK 
than Pakistan due to lower risk of death both within the 
trial, and beyond the trial period, for those in the UK 
compared with Pakistan.
Deterministic sensitivity analysis
A number of deterministic sensitivity analyses were 
performed. While the estimated ICERs varied 
Table 2 Base- case cost- effectiveness results for mild and moderate TBI patients treated with and without tranexamic acid in 
the UK and Pakistan
Costs LYs QALYs ICER (LY) ICER (QALY)
CE threshold 
(per QALY)
Probability 
CE at 
threshold
UK
  Placebo £55 110 16.87 12.10
  Tranexamic acid £55 869 17.12 12.28 £3078 £4288 £20 000 99%
Pakistan
  Placebo US$92 14.97 10.83
  Tranexamic acid US$97 15.26 11.04 US$17 US$24 US$158 98%
CE, cost- effectiveness; ICER, incremental cost- effectiveness ratio; LY, life- years; QALY, quality- adjusted life- years; TBI, traumatic brain injury.
Figure 2 Cost- effectiveness acceptability curve for tranexamic acid for patients with mild or moderate traumatic brain injury 
in (A) the UK and (B) Pakistan. Dotted lines represent willingness to pay per QALY thresholds for UK (£20 000) and Pakistan 
(US$158). GBP, costs in pound; QALY, quality- adjusted life years; USD, US dollars.
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considerably by setting, tranexamic acid remained cost- 
effective across all sensitivity analyses in both settings, 
with all ICERs below the willingness to pay thresholds 
(figure 3).
For the UK, the largest increase in the ICER per QALY 
resulted when assuming a lower utility for those receiving 
tranexamic acid (0.74) compared with placebo (0.75) 
based on trial DRS scores, increasing the ICER to £14 465. 
Restricting monitoring costs to only the first year or first 
5 years postinjury reduced the ICER to £979 and £1646, 
respectively. Assuming a lower utility for both groups 
(0.63) increased the ICER to £5112. A sensitivity anal-
ysis considering a head injury death risk ratio of 0.95 for 
tranexamic acid (ie, a smaller reduction in head injury 
deaths associated with treatment) resulted in a small 
increase in the ICER to £4721.
For Pakistan, the results were most sensitive to the risk 
ratio of head injury death associated with tranexamic 
acid. When increasing the risk ratio to 0.95, the ICER 
increased to US$107, while reducing it to 0.64 reduced 
the ICER to US$15. Assuming a lower utility for those 
receiving tranexamic acid compared with placebo 
increased the ICER to US$52. The remaining sensitivity 
analyses had minimal impact on the ICER, with none 
influencing the cost- effectiveness decision.
For mild and moderate TBI patients treated within 
3 hours of injury, the tranexamic acid risk ratio for head 
injury death is lower with earlier treatment administra-
tion. A sensitivity analysis showed that earlier treatment 
administration, within 2 hours of injury, was associated 
with greater cost- effectiveness (lower ICERs) compared 
with our base- case results, in both settings. For example, 
if tranexamic was provided 30 min after injury, the esti-
mated ICERs would fall to £4236 per QALY in the UK, 
and US$14 per QALY in Pakistan, based on an estimated 
head injury death risk ratio of 0.62. Full results, by 30 min 
intervals from injury to treatment, are available in the 
online supplementary materials.
Tranexamic acid remained cost- effective when consid-
ering a short- term time horizon of 5 years, with ICERs of 
£6489 and US$89 for the UK and Pakistan.
Alternative model populations
When considering patients sustaining a TBI of any severity 
with both pupils reactive, tranexamic acid treatment 
remained highly cost- effective. The ICERs were £6097/
QALY in the UK and US$24/QALY in Pakistan, and 99% 
and 97% likely to be cost- effective at the assumed cost- 
effectiveness thresholds, respectively.
Figure 3 Tornado diagram showing deterministic sensitivity analyses and the impact on the ICER, in the UK and Pakistan. 
GBP, costs in pound; ICER, incremental cost- effectiveness ratio; QALY, quality- adjusted life years; TXA, tranexamic acid; USD, 
US dollar.
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For patients in high- income countries sustaining a severe 
TBI, there is uncertainty around the cost- effectiveness of 
providing tranexamic acid. The ICERs were £18 519 for 
all severe patients, and £18 672 in a subgroup of severe 
patients but excluding those with a GCS score of 3 or 
bilateral unreactive pupils. In probabilistic sensitivity 
analyses of these two groups, tranexamic acid was 62% 
and 65% likely to be cost- effective at the £20 000/QALY 
threshold, respectively. At £30 000/QALY, the upper limit 
of the NICE cost- effectiveness threshold, tranexamic acid 
was 86% and 98% likely to be cost- effective in these two 
groups. Full results for these analyses are available in the 
online supplementary materials.
DISCUSSION
Of the estimated 69 million TBI’s that occur globally each 
year, 55.9 million are mild and 7.6 million are moderate 
TBIs. Those with mild TBI and evidence of intracranial 
bleeding, and those with moderate TBI who receive 
tranexamic acid within 3 hours have a considerable 
reduction in their risk of head injury death, meaning 
treatment could potentially save many thousands of lives 
globally each year. While the cost of treatment is low, 
providing treatment will still incur additional costs to the 
health service. Our analysis shows that tranexamic acid 
is a highly cost- effective treatment in both high- income 
and lower- middle income settings for those with mild or 
moderate TBI, and is also cost- effective when treating 
patients with both pupils reactive. The results for those 
with mild and moderate TBI were also robust across sensi-
tivity analyses, with tranexamic acid 99% and 98% likely 
to be cost- effective in the UK and Pakistan, respectively.
When putting the results of our analysis into context, 
tranexamic acid was cost- effective across vastly different 
healthcare settings. Treatment remained highly cost- 
effective at a relatively low cost- effectiveness threshold of 
11% of GDP per capita for Pakistan, which is one of the 
lowest cost- effectiveness thresholds globally. In addition, 
the US$24 per QALY ICER for Pakistan is lower than 
any country’s cost- effectiveness threshold, as reported by 
Ochalek et al.28 It also remains considerably lower than 
the cost- effectiveness threshold range estimated for Paki-
stan (US$106–US$815) by Woods et al.30 This suggests 
that tranexamic acid for mild and moderate patients is 
likely to be cost- effective across all income settings.
In the UK, tranexamic acid was highly cost- effective, 
and remained cost- effective across all sensitivity anal-
yses. NICE guidelines included tranexamic acid for the 
prehospital care of patients with trauma, following the 
results of the CRASH-2 trial.31 Our analysis suggests 
that early administration of tranexamic acid is also 
highly cost- effective and should be recommended for 
patients with moderate TBI and mild TBI with intra-
cranial bleeding. There was considerable uncertainty 
in the cost- effectiveness of tranexamic acid for patients 
with severe TBI in the UK, although treatment was more 
likely to be cost- effective than not at the £20 000/QALY 
cost- effectiveness threshold. Treatment was highly likely 
to be cost- effective at cost- effectiveness threshold of £30 
000/QALY.
The CRASH-3 trial showed that earlier treatment 
administration resulted in a greater reduction in head 
injury deaths for those sustaining a mild or moderate 
TBI. This relationship was unknown during the trial, and 
the randomisation process also required additional time 
prior to treatment. Therefore, tranexamic acid is likely 
to be even more cost- effective than our results suggest if 
the time to treatment administration is reduced in a real- 
world setting, as demonstrated in a sensitivity analysis. 
In the CRASH-3 trial, tranexamic acid was administered 
in the emergency department, but this finding would 
support its administration in the prehospital setting (eg, 
at the location of injury or in the ambulance), where 
possible.
To our knowledge, this is the first cost- effectiveness 
analysis of tranexamic acid for patients sustaining a TBI. 
Our results are similar to those of previous economic 
evaluations for tranexamic acid in postpartum haemor-
rhage, trauma patients with significant haemorrhage and 
patients experiencing bleeding during the surgery.6 7 32 
These studies have also shown tranexamic acid to be cost- 
effective, with relatively low incremental costs associated 
with providing treatment.
Our analysis has considerable strengths, but also some 
limitations. The analysis uses data taken from a large, 
multinational RCT, and therefore, the evidence of the 
treatment effect can be considered of high quality. In 
addition, our analysis showed the intervention is highly 
likely to be cost- effective in both high- income and low- 
income settings. However, one limitation of our analysis is 
that the CRASH-3 trial only followed patients for 28 days 
postinjury, leading to uncertainty in patient outcomes 
beyond this time. Data on the long- term outcomes post-
head injury are relatively scarce in the literature, particu-
larly for LMICs. We assumed that after the trial period the 
risk of death remained considerably elevated compared 
with the general population (four times higher for first 
year, two times higher thereafter), to capture the long- 
term additional risk of death compared with the general 
population. These elevated risks were derived from Scot-
land, and therefore, may differ for low- income countries. 
However, sensitivity analyses using higher discount rates 
(giving lower weighting to future events), and a scenario 
excluding this additional mortality both had little impact 
on the estimated ICER, with tranexamic acid remaining 
cost- effective in both analyses.
Additionally, the CRASH-3 trial did not collect direct 
utility estimates, meaning that they were estimated from 
the DRS outcomes at 28 days (or at time of discharge). 
While just over half of all mild and moderate patients 
had no disability at discharge, there was uncertainty in 
the average utility of CRASH-3 trial patients, as these data 
were not collected in the trial. There was also uncertainty 
regarding the long- term disability of patients beyond 28 
days. While studies have tended to show an improvement 
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in functional outcomes up to 1- year postinjury (suggesting 
the utility may initially improve beyond the 28- day trial 
period), a long- term study over 7 years showed that func-
tional outcomes post- TBI can improve or deteriorate 
over time.33 A limitation of our model is that we did 
not capture potential long- term changes in functional 
outcomes, instead only using outcomes reported in the 
trial period to capture quality of life. However, sensitivity 
analyses considering higher and lower utility values had 
little impact on the ICER in either setting, and did not 
change the cost- effectiveness decision.
Lastly, our analysis was performed from a health service 
perspective, and therefore, did not capture the poten-
tial long- term costs associated with caregiver burden or 
out- of- pocket medical payments for those living with 
disability. This may be particularly burdensome in low- 
income settings, where there may be more emphasis on 
the family providing care to individuals with disabilities. 
However, it should be noted that as the disability scores 
for survivors between the groups is similar, any additional 
societal burden associated with tranexamic acid treat-
ment would only result from the higher proportion of 
patients surviving when receiving this treatment.
CONCLUSION
We have used results from a large, multinational trial to 
show that the early administration of tranexamic acid is a 
highly cost- effective treatment for people with moderate 
TBI and mild TBI with intracranial bleeding, in the UK 
and Pakistan. Furthermore, our results suggest treatment 
is likely to be cost- effective across all income settings.
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